'Am I My Genes?': Fate, Family And Genetic Testing
By NPR Staff,
National Public Radio
| 02. 27. 2012
Advances in genetic testing have improved the prediction, diagnosis and treatment of disease. But having increased information about your genetic makeup can raise some difficult questions and decisions.
Dr. Robert Klitzman wades through some of those challenges in Am I My Genes?: Confronting Fate and Family Secrets in the Age of Genetic Testing. For the book, Klitzman interviewed 64 people whose genetics indicate they might be at risk for Huntington's disease, breast cancer and other illnesses. These individuals faced a number of big choices: the decision to be tested in the first place, whether to reveal the results to family members and doctors, and how to plan for the future.
"People suddenly had to wrestle: Do I tell my 18-year-old son or daughter or my 17-year-old or my 21-year-old child that he or she therefore also has a 50 percent chance of having this mutation? Do I want to have that shadow their lives as they're just getting going on their independent adult lives?" Klitzman tells NPR's John Donvan.
Scientists have isolated thousands of genetic markers that indicate clear...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...